Aditya Birla Sun Life International Equity Fund vs Tata India Pharma & Healthcare Fund
Direct Plan, Growth option · Data as on 29-10-2026
Aditya Birla Sun Life International Equity Fund is a Thematic fund and Tata India Pharma & Healthcare Fund is a Thematic fund. In the 3 years to 30-10-2026, Aditya Birla Sun Life International Equity Fund (Direct) returned 24.5% a year and Tata India Pharma & Healthcare Fund (Direct) returned 19.3% a year. Aditya Birla Sun Life International Equity Fund charges 2.00% a year and Tata India Pharma & Healthcare Fund 1.10% (Direct plans). Their portfolios overlap 0.0%: they hold 0 of the same securities.
Aditya Birla Sun Life International Equity Fund
Thematic
- 3 year return
- 24.5%
- Expense ratio
- 2.00%
- NAV
- ₹56.75
Tata India Pharma & Healthcare Fund
Thematic
- 3 year return
- 19.3%
- Expense ratio
- 1.10%
- NAV
- ₹37.77
Which is better, Aditya Birla Sun Life International Equity or Tata India Pharma & Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Tata India Pharma & Healthcare returned more over 5 years: 14.9% a year against 11.9%.
- Aditya Birla Sun Life International Equity returned more over 3 years: 24.5% a year against 19.3%.
- Tata India Pharma & Healthcare costs less: 1.10% a year against 2.00% (Direct plans).
- Aditya Birla Sun Life International Equity swung less over 3 years: a standard deviation of 12.3% a year against 13.2%.
- Tata India Pharma & Healthcare fell less in its worst fall since 29-12-2015: −19.8% against −27.5%.
- Aditya Birla Sun Life International Equity holds 93.5% of the fund in foreign stocks; Tata India Pharma & Healthcare 0.0%.
- Tata India Pharma & Healthcare holds more in large companies: 26.0% of the fund in large caps against 0.0%.
- Tata India Pharma & Healthcare is the larger fund: ₹1,511 Cr against ₹352 Cr.
- Their portfolios overlap 0.0%: 0 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Aditya Birla Sun Life International Equity Fund | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Fund house | Aditya Birla Sun Life Mutual Fund | Tata Mutual Fund |
| Category | Thematic | Thematic |
| AUM | ₹352 Cr (30-09-2026) | ₹1,511 Cr (30-09-2026) |
| NAV | ₹56.75 (Direct) | ₹37.77 (Direct) |
| Expense ratio (Direct) | 2.00% | 1.10% |
| Expense ratio (Regular) | 2.55% | 2.42% |
| Riskometer | Very High | Very High |
| Benchmark | S&P Global 1200 TRI | BSE Healthcare TRI |
| Launch date | 31-10-2007 | 28-12-2015 |
| Minimum investment | ₹1,000 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Dhaval Joshi | Rajat Srivastava |
| Exit load | Exit load of 1%, if redeemed within 30 days. | 0.25% of NAV if redeemed /switched out before 30 days from the date of allotment. |
Aditya Birla Sun Life International Equity vs Tata India Pharma & Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Aditya Birla Sun Life International Equity Fund (Direct) | −1.59% | +3.00% | +4.05% | +13.97% | +24.46% | +11.86% | +13.70% |
| Tata India Pharma & Healthcare Fund (Direct) | −1.40% | −5.00% | +6.91% | +4.28% | +19.28% | +14.93% | +14.64% |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | +11.62% | +13.76% |
Category average: the average of the 235 Thematic funds, same plan type.
Aditya Birla Sun Life International Equity vs Tata India Pharma & Healthcare: Year-wise Returns
| Year | Aditya Birla Sun Life International EquityAditya Birla Sun Life International Equity | Tata India Pharma & HealthcareTata India Pharma & Healthcare |
|---|---|---|
| 2026to date | +12.49% | +6.77% |
| 2025 | +35.28% | −3.47% |
| 2024 | +8.06% | +42.48% |
| 2023 | +9.37% | +38.59% |
| 2022 | −1.36% | −6.64% |
| 2021 | +14.47% | +20.88% |
Aditya Birla Sun Life International Equity vs Tata India Pharma & Healthcare: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of Tata India Pharma & Healthcare Fund
Rolling returns
Every 3-year holding period, 1,931 of them, one for each trading day from 31-12-2018 to 29-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Aditya Birla Sun Life International Equity Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
to
Aug 2019Dec 2017
to
Dec 2020Apr 2019
to
Apr 2022Aug 2020
to
Aug 2023Dec 2021
to
Dec 2024Mar 2023
to
Mar 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aditya Birla Sun Life International Equity | 0.0 | 5.4 | 25.6 | 45.0 | 19.1 | 4.8 | 0.0 | 12.1% | 12.4% | 2.1% | 24.5% | 25% |
| Tata India Pharma & Healthcare | 9.1 | 5.7 | 2.8 | 3.1 | 21.3 | 38.2 | 19.6 | 18.2% | 21.2% | −3.4% | 30.5% | 83% |
| BSE Healthcare TRI | 16.5 | 1.5 | 2.2 | 14.0 | 23.3 | 33.7 | 8.8 | 15.4% | 19.0% | −9.9% | 28.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 29-12-2015. Past returns do not promise future returns.
Aditya Birla Sun Life International Equity vs Tata India Pharma & Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 01-12-2015 to 29-10-2026: 131 instalments, ₹13,10,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Aditya Birla Sun Life International EquityAditya Birla Sun Life International Equity Fund (Direct) | ₹13,10,000 | ₹28,96,797 | ₹15,86,797 | 13.8% |
| Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct) | ₹13,10,000 | ₹34,72,173 | ₹21,62,173 | 16.9% |
Aditya Birla Sun Life International EquityAditya Birla Sun Life International Equity Fund (Direct)
Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Aditya Birla Sun Life International Equity vs Tata India Pharma & Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Aditya Birla Sun Life International Equity Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +13.97% | +4.28% |
| Standard deviation | 13.70% | 11.99% |
| Sharpe ratio | 0.64 | -0.08 |
| Sortino ratio | 0.89 | -0.11 |
| Maximum drawdown | −8.3% (30-03-2026) | −11.0% (23-10-2026) |
| Beta | -- | 0.82 |
| Alpha | -- | −6.83% |
From daily NAVs, 29-10-2025 to 29-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Aditya Birla Sun Life International Equity Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +24.46% | +19.28% |
| Standard deviation | 12.33% | 13.21% |
| Sharpe ratio | 1.49 | 1.00 |
| Sortino ratio | 2.16 | 1.43 |
| Maximum drawdown | −13.9% (07-04-2025) | −16.8% (28-02-2025) |
| Beta | -- | 0.89 |
| Alpha | -- | −1.91% |
From daily NAVs, 27-10-2023 to 29-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Aditya Birla Sun Life International Equity Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +11.86% | +14.93% |
| Standard deviation | 14.14% | 12.92% |
| Sharpe ratio | 0.43 | 0.71 |
| Sortino ratio | 0.61 | 1.01 |
| Maximum drawdown | −16.6% (03-10-2022) | −16.8% (28-02-2025) |
| Beta | -- | 0.89 |
| Alpha | -- | +0.41% |
From daily NAVs, 29-10-2021 to 29-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Aditya Birla Sun Life International Equity Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +11.96% | +13.01% |
| Standard deviation | 14.26% | 15.08% |
| Sharpe ratio | 0.41 | 0.50 |
| Sortino ratio | 0.58 | 0.72 |
| Maximum drawdown | −27.5% (24-03-2020) | −19.8% (21-08-2017) |
| Beta | -- | 0.87 |
| Alpha | -- | +2.53% |
From daily NAVs, 02-01-2013 to 29-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Aditya Birla Sun Life International Equity Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life International Equity Fund (Direct) | −27.5% | 20-02-2020 | 24-03-2020 | 09-06-2020 | 3 months | −3.4% |
| Tata India Pharma & Healthcare Fund (Direct) | −19.8% | 01-02-2016 | 21-08-2017 | 31-08-2018 | 12 months | −6.0% |
| BSE Healthcare TRI | −33.2% | 29-12-2015 | 23-03-2020 | 22-06-2020 | 3 months | −3.8% |
From daily values since 29-12-2015, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Aditya Birla Sun Life International Equity Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Aditya Birla Sun Life International Equity Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 5-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Aditya Birla Sun Life International Equity Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Aditya Birla Sun Life International Equity Fund (Direct) | 36% | -7% | 18.42% |
| Tata India Pharma & Healthcare Fund (Direct) | 92% | 79% | 4.99% |
From month-end values since 29-12-2015. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Aditya Birla Sun Life International Equity vs Tata India Pharma & Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: Aditya Birla Sun Life International Equity Fund, September 2026; Tata India Pharma & Healthcare Fund, September 2026
Holdings in common
- Overlap
- 0.0%
- Held by both
- 0
- Only in Aditya Birla Sun Life International Equity
- 0
- Only in Tata India Pharma & Healthcare
- 41
Overlap: for each holding both funds own, the smaller of its two weights, added up. 0.0% means 0.0% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Aditya Birla Sun Life International Equity Fund
Every holding of this fund is also held by the other.
Largest holdings only in Tata India Pharma & Healthcare Fund
| Security | % of fund |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD | 7.99% |
| ABBOTT INDIA LTD | 5.94% |
| HEALTHCARE GLOBAL ENTERPRISES LTD | 5.92% |
| DIVI LABORATORIES LTD | 5.68% |
| DR REDDYS LABORATORIES LTD | 4.65% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Aditya Birla Sun Life International Equity | Tata India Pharma & Healthcare |
|---|---|---|
| Equity | 93.5% | 99.7% |
| Debt | 0.0% | 0.0% |
| Cash and others | 6.5% | 0.3% |
Market cap of stocks
| Market cap | Aditya Birla Sun Life International Equity | Tata India Pharma & Healthcare |
|---|---|---|
| Large Cap | 0.0% | 26.0% |
| Mid Cap | 0.0% | 33.9% |
| Small Cap | 0.0% | 37.0% |
| Foreign stocks | 93.5% | 0.0% |
| Not on AMFI's list | 0.0% | 2.9% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Aditya Birla Sun Life International Equity | Tata India Pharma & Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 8.3% | 60.6% |
| Healthcare Services | 0.0% | 27.8% |
| IT - Software | 15.0% | 0.0% |
| IT - Hardware | 7.7% | 0.0% |
| Fertilizers & Agrochemicals | 0.0% | 6.9% |
| Retailing | 6.6% | 0.0% |
| Banks | 5.5% | 0.0% |
| Industrial Manufacturing | 5.2% | 0.0% |
| Chemicals & Petrochemicals | 1.6% | 2.6% |
| Personal Products | 0.0% | 1.2% |
| Healthcare Equipment & Supplies | 0.0% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Aditya Birla Sun Life International Equity vs Tata India Pharma & Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Aditya Birla Sun Life International Equity Fund | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 2.00% | 1.10% |
| Base expense ratio (Direct) | 1.60% | 0.64% |
| Total expense ratio (Regular) | 2.55% | 2.42% |
| Base expense ratio (Regular) | 2.08% | 1.82% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Aditya Birla Sun Life International Equity with
Aditya Birla Sun Life International Equity Fund vs Tata India Pharma & Healthcare Fund: Frequently Asked Questions
What is the difference between Aditya Birla Sun Life International Equity Fund and Tata India Pharma & Healthcare Fund?
Aditya Birla Sun Life International Equity Fund is a Thematic fund, Tata India Pharma & Healthcare Fund is a Thematic fund, run by Aditya Birla Sun Life Mutual Fund and Tata Mutual Fund. Their portfolios overlap 0.0%. Aditya Birla Sun Life International Equity Fund charges 2.00% a year and Tata India Pharma & Healthcare Fund 1.10%.
Which has given higher returns, Aditya Birla Sun Life International Equity Fund or Tata India Pharma & Healthcare Fund?
Over 1 year: Aditya Birla Sun Life International Equity Fund +13.97%, Tata India Pharma & Healthcare Fund +4.28%. Over 3 years: Aditya Birla Sun Life International Equity Fund +24.46% a year, Tata India Pharma & Healthcare Fund +19.28% a year. Over 5 years: Aditya Birla Sun Life International Equity Fund +11.86% a year, Tata India Pharma & Healthcare Fund +14.93% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Aditya Birla Sun Life International Equity Fund or Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund charges less: 1.10% a year against 2.00%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Aditya Birla Sun Life International Equity Fund and Tata India Pharma & Healthcare Fund overlap?
0.0%. They hold 0 of the same securities. From each fund's latest monthly portfolio.
Which is riskier, Aditya Birla Sun Life International Equity Fund or Tata India Pharma & Healthcare Fund?
On SEBI's riskometer, Aditya Birla Sun Life International Equity Fund is rated Very High and Tata India Pharma & Healthcare Fund Very High. Over 3 years, the standard deviation of daily returns was 12.33% and 13.21% a year.
Which is better for SIP, Aditya Birla Sun Life International Equity Fund or Tata India Pharma & Healthcare Fund?
Over the last 5 years, a monthly SIP of ₹10,000 from 01-10-2021 to 29-10-2026 grew to ₹9,41,185 in Aditya Birla Sun Life International Equity Fund (XIRR 17.1% a year) and ₹9,10,986 in Tata India Pharma & Healthcare Fund (XIRR 15.8% a year). Both received 61 instalments. Past returns do not promise future returns.
Can I invest in both Aditya Birla Sun Life International Equity Fund and Tata India Pharma & Healthcare Fund?
Yes. 0.0% of each fund's money sits in the same holdings, so the two hold mostly different investments.
Who manages Aditya Birla Sun Life International Equity Fund and Tata India Pharma & Healthcare Fund?
Aditya Birla Sun Life International Equity Fund: Dhaval Joshi. Tata India Pharma & Healthcare Fund: Rajat Srivastava.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.